Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study

Author:

Takata Saori1,Morikawa Kei2ORCID,Tanaka Hisashi3,Itani Hidetoshi4,Ishihara Masashi5,Horiuchi Kazuya6,Kato Yasuhiro7ORCID,Ikemura Shinnosuke8,Nakagawa Hideyuki9,Nakahara Yoshiro10,Seki Yoshitaka11,Bessho Akihiro12ORCID,Takahashi Nobumasa13,Hayashi Kentaro14,Endo Takeo15,Takeyama Kiyoshi16,Maekura Toshiya17,Takigawa Nagio18ORCID,Kawase Akikazu19,Endoh Makoto20,Nemoto Kenji21,Kishi Kazuma22,Soejima Kenzo8,Okuma Yusuke7,Yoshimura Kenichi23,Saigusa Daisuke24,Kanai Yae25,Ueda Koji26,Togashi Akira27,Matsutani Noriyuki28,Seki Nobuhiko29

Affiliation:

1. Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan

2. Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

3. Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Aomori, Japan

4. Department of Respiratory Medicine, Ise Red Cross Hospital, Mie, Japan

5. Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

6. Respiratory Disease Center, Showa University Northern Yokohama Hospital, Kanagawa, Japan

7. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

8. Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan

9. Department of Respiratory Medicine, National Hospital Organization Hirosaki Hospital, Aomori, Japan

10. Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan

11. Department of Internal Medicine, The Jikei University Daisan Hospital, Tokyo, Japan

12. Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan

13. Department of General Thoracic Surgery, Saitama Cardiovascular and Respiratory Center, Saitama, Japan

14. Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

15. Department of Respiratory Medicine, National Hospital Organization Mito Medical Center, Ibaraki, Japan

16. Department of Respiratory Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

17. Department of Respiratory Medicine, Hoshigaoka Medical Center, Osaka, Japan

18. Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan

19. First Department of Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan

20. Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan

21. Department of Respiratory Medicine, National Hospital Organization, Ibarakihigashi National Hospital, Ibaraki, Japan

22. Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo, Japan

23. Department of Biostatistics, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan

24. Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan

25. Department of Pathology, Keio University School of Medicine, Tokyo, Japan

26. Project for Realization of Personalized Cancer Medicine, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan

27. Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

28. Department of Surgery, Teikyo University Hospital, Mizonokuchi, Kanagawa, Japan

29. Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan

Abstract

Background: The exosome-focused translational research for afatinib (EXTRA) study is the first trial to identify novel predictive biomarkers for longer treatment efficacy of afatinib in patients with epidermal growth factor receptor ( EGFR) mutation-positive nonsmall cell lung cancer (NSCLC) via a comprehensive association study using genomic, proteomic, epigenomic, and metabolomic analyses. Objectives: We report details of the clinical portion prior to omics analyses. Design: A prospective, single-arm, observational study was conducted using afatinib 40 mg/day as an initial dose in untreated patients with EGFR mutation-positive NSCLC. Dose reduction to 20 mg every other day was allowed. Methods: Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated. Results: A total of 103 patients (median age 70 years, range 42–88 years) were enrolled from 21 institutions in Japan between February 2017 and March 2018. After a median follow-up of 35.0 months, 21% remained on afatinib treatment, whereas 9% had discontinued treatment because of AEs. The median PFS was 18.4 months, with a 3-year PFS rate of 23.3%. The median afatinib treatment duration in patients with final doses of 40 ( n = 27), 30 ( n = 23), and 20 mg/day ( n = 35), and 20 mg every other day ( n = 18) were 13.4, 15.4, 18.8, and 18.3 months, respectively. The median OS was not reached, with a 3-year OS rate of 58.5%. The median OS in patients who did ( n = 25) and did not ( n = 78) receive osimertinib during the entire course of treatment were 42.4 months and not reached, respectively ( p = 0.654). Conclusions: As the largest prospective study in Japan, this study confirmed favorable OS following first-line afatinib in patients with EGFR mutation-positive NSCLC in a real-world setting. Further analysis of the EXTRA study is expected to identify novel predictive biomarkers for afatinib. Trial registration: UMIN-CTR identifier (UMIN000024935, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_his_list.cgi?recptno=R000028688

Funder

Boehringer Ingelheim

Publisher

SAGE Publications

Subject

Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3